OncoMatch/Clinical Trials/NCT05917158
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
Is NCT05917158 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies RC48-ADC and JS001 for carcinoma.
Treatment: RC48-ADC and JS001 — This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (2~3+)
Pathological tissue immunohistochemistry HER2 2~3+
Disease stage
Required: Stage PT2-PT4 PN0-2 M0, PTANY N1-2 M0
Histologically confirmed TCC staged pT2-pT4 pN0-2 M0 or pTany N1-2 M0 (providing all grossly abnormal nodes are resected)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radical nephro-ureterectomy — postoperative
Post radical nephro-ureterectomy for upper tract tumour
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05917158 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radical nephro-ureterectomy.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage PT2-PT4 PN0-2 M0 or PTANY N1-2 M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages